MX2021014235A - Formas en estado sólido. - Google Patents

Formas en estado sólido.

Info

Publication number
MX2021014235A
MX2021014235A MX2021014235A MX2021014235A MX2021014235A MX 2021014235 A MX2021014235 A MX 2021014235A MX 2021014235 A MX2021014235 A MX 2021014235A MX 2021014235 A MX2021014235 A MX 2021014235A MX 2021014235 A MX2021014235 A MX 2021014235A
Authority
MX
Mexico
Prior art keywords
forms
solid state
fluoro
methyl
salt form
Prior art date
Application number
MX2021014235A
Other languages
English (en)
Spanish (es)
Inventor
Stephan D Parent
Mary Chaves
Ron C Kelly
Prashant Agarwal
Roman Shimanovich
Darren Leonard Reid
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2021014235A publication Critical patent/MX2021014235A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
MX2021014235A 2019-05-21 2020-05-20 Formas en estado sólido. MX2021014235A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962851049P 2019-05-21 2019-05-21
PCT/US2020/033832 WO2020236948A1 (en) 2019-05-21 2020-05-20 Solid state forms

Publications (1)

Publication Number Publication Date
MX2021014235A true MX2021014235A (es) 2022-03-11

Family

ID=71016701

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021014235A MX2021014235A (es) 2019-05-21 2020-05-20 Formas en estado sólido.
MX2025010774A MX2025010774A (es) 2019-05-21 2021-11-19 Formas en estado solido

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2025010774A MX2025010774A (es) 2019-05-21 2021-11-19 Formas en estado solido

Country Status (10)

Country Link
US (1) US12252486B2 (cg-RX-API-DMAC7.html)
EP (1) EP3972972A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022532790A (cg-RX-API-DMAC7.html)
AR (1) AR119741A1 (cg-RX-API-DMAC7.html)
AU (2) AU2020277398B2 (cg-RX-API-DMAC7.html)
CA (1) CA3140394A1 (cg-RX-API-DMAC7.html)
MX (2) MX2021014235A (cg-RX-API-DMAC7.html)
TW (1) TW202110836A (cg-RX-API-DMAC7.html)
UY (1) UY38711A (cg-RX-API-DMAC7.html)
WO (1) WO2020236948A1 (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20190338A (es) 2016-12-22 2019-09-09 Amgen Inc Inhibidores de kras g12c y métodos para su uso
UA127968C2 (uk) 2017-05-22 2024-02-28 Емджен Інк. Інгібітори g12c kras і способи їх застосування
US10640504B2 (en) 2017-09-08 2020-05-05 Amgen Inc. Inhibitors of KRAS G12C and methods of using the same
MX2020010836A (es) 2018-05-04 2021-01-08 Amgen Inc Inhibidores de kras g12c y métodos para su uso.
EP3788053B1 (en) 2018-05-04 2024-07-10 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
WO2019217691A1 (en) 2018-05-10 2019-11-14 Amgen Inc. Kras g12c inhibitors for the treatment of cancer
WO2019232419A1 (en) 2018-06-01 2019-12-05 Amgen Inc. Kras g12c inhibitors and methods of using the same
AU2019284472B2 (en) 2018-06-11 2024-05-30 Amgen Inc. KRAS G12C inhibitors for treating cancer
JP7369719B2 (ja) 2018-06-12 2023-10-26 アムジエン・インコーポレーテツド KRas G12C阻害剤及びそれを使用する方法
US12208099B2 (en) 2018-09-10 2025-01-28 Mirati Therapeutics, Inc. Combination therapies
SMT202500028T1 (it) 2018-09-10 2025-03-12 Mirati Therapeutics Inc Terapie combinate
AU2019338207B2 (en) 2018-09-10 2025-01-02 Mirati Therapeutics, Inc. Combination therapies
CA3112043A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
JP7516029B2 (ja) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Kras g12c阻害剤化合物の重要な中間体の改良合成法
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
JP7454572B2 (ja) 2018-11-19 2024-03-22 アムジエン・インコーポレーテツド Kras g12c阻害剤及びその使用方法
US12377101B2 (en) 2018-12-05 2025-08-05 Mirati Therapeutics, Inc. Combination therapies
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
EP3972973A1 (en) 2019-05-21 2022-03-30 Amgen Inc. Solid state forms
US12252486B2 (en) 2019-05-21 2025-03-18 Amgen Inc. Solid state forms
CN114615981B (zh) 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
CN114761012B (zh) 2019-09-24 2025-03-21 米拉蒂治疗股份有限公司 组合疗法
PH12022551513A1 (en) 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
US20230183235A1 (en) * 2020-05-20 2023-06-15 Teva Pharmaceuticals International Gmbh Solid state forms of amg-510 and process for preparation thereof
WO2021249563A1 (zh) * 2020-06-12 2021-12-16 苏州泽璟生物制药股份有限公司 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
US12655160B2 (en) 2020-08-04 2026-06-16 Mirati Therapeutics, Inc. KRAS G12D inhibitors
EP4210833A4 (en) 2020-09-11 2024-09-11 Mirati Therapeutics, Inc. CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR
EP4216951B1 (en) 2020-09-22 2026-04-01 Mirati Therapeutics, Inc. Kras g12d inhibitors
JP2023551006A (ja) * 2020-11-26 2023-12-06 上▲海▼翰森生物医▲薬▼科技有限公司 窒素含有複素環誘導体の塩、結晶、並びにその調製方法、及び使用
EP4262807A4 (en) 2020-12-15 2025-04-23 Mirati Therapeutics, Inc. Azachinazoline pan-KRAS inhibitors
WO2022133038A1 (en) 2020-12-16 2022-06-23 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
WO2022246069A1 (en) 2021-05-19 2022-11-24 Teva Pharmaceuticals International Gmbh Process for preparation of sotorasib and solid state form thereof
CN114605406B (zh) * 2021-09-18 2023-05-26 都创(上海)医药开发有限公司 Amg510化合物的晶型及其制备方法和用途
CN115368358A (zh) * 2022-09-01 2022-11-22 浙江九洲药业股份有限公司 一种Sotorasib新晶型及其制备方法与应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201312059D0 (en) 2013-07-05 2013-08-21 Univ Leuven Kath Novel GAK modulators
MX380928B (es) 2013-10-10 2025-03-12 Araxes Pharma Llc Inhibidores de kras g12c.
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Kras g12c之抑制劑
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
AU2016245864C1 (en) 2015-04-10 2021-09-09 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
ES2863873T3 (es) 2016-05-18 2021-10-11 Mirati Therapeutics Inc Inhibidores de KRAS G12C
CR20190338A (es) 2016-12-22 2019-09-09 Amgen Inc Inhibidores de kras g12c y métodos para su uso
UA127968C2 (uk) * 2017-05-22 2024-02-28 Емджен Інк. Інгібітори g12c kras і способи їх застосування
US10640504B2 (en) 2017-09-08 2020-05-05 Amgen Inc. Inhibitors of KRAS G12C and methods of using the same
MX2020010836A (es) 2018-05-04 2021-01-08 Amgen Inc Inhibidores de kras g12c y métodos para su uso.
JP7516029B2 (ja) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Kras g12c阻害剤化合物の重要な中間体の改良合成法
US12252486B2 (en) 2019-05-21 2025-03-18 Amgen Inc. Solid state forms
EP3972973A1 (en) 2019-05-21 2022-03-30 Amgen Inc. Solid state forms
EP4700030A3 (en) 2019-11-14 2026-03-18 Amgen, Inc. Improved synthesis of kras g12c inhibitor compound
CA3161156A1 (en) 2019-11-14 2021-05-20 Amgen Inc. Improved synthesis of kras g12c inhibitor compound

Also Published As

Publication number Publication date
UY38711A (es) 2020-11-30
AU2026200455A1 (en) 2026-02-12
JP2025131597A (ja) 2025-09-09
TW202110836A (zh) 2021-03-16
JP2022532790A (ja) 2022-07-19
MX2025010774A (es) 2025-10-01
AU2020277398B2 (en) 2026-01-29
US20220235045A1 (en) 2022-07-28
AR119741A1 (es) 2022-01-05
WO2020236948A1 (en) 2020-11-26
US12252486B2 (en) 2025-03-18
CA3140394A1 (en) 2020-11-26
AU2020277398A1 (en) 2021-12-09
EP3972972A1 (en) 2022-03-30

Similar Documents

Publication Publication Date Title
MX2025010774A (es) Formas en estado solido
NZ782284A (en) Solid state forms
MX391723B (es) Composiciones de forma de dosificacion que comprenden un inhibidor de tirosina cinasa de bruton.
IL319470A (en) History of 4-(8,3-diazabicyclo[1.2.3]octan-3-yl)-7-naphthalene-pyrido[3,4-D]pyrimidine as inhibitors of mutant KRAS(G12D) oncoprotein for cancer treatment
WO2016142855A3 (en) Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors
GEAP202215475A (en) 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors
PH12018500532A1 (en) 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2- one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer
CY1120248T1 (el) Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου
TW200607505A (en) Fused heterocyclic kinase inhibitors
EA201890318A1 (ru) СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
IL203258A (en) Terroyl pyridyl and phenyl benzencephalonamides, containing pharmaceuticals and their use in the treatment of conditions or diseases mediating 2ccr
EA201892436A1 (ru) Пиримидиновые соединения в качестве ингибиторов jak киназы
IL275059A (en) 5-(2-(5,2-difluorophenyl)pyrrolidin-1-yl)-3-(1H-pyrazol-1-yl)pyrazolo[5,1-A]pyrimidine derivatives and related compounds as TRK kinase inhibitors for cancer therapy
MY148375A (en) Delta and epsilon crystal forms of imatinib mesylate
ZA201901321B (en) Tablet compositions
SG10201810057UA (en) Crystalline fgfr4 inhibitor compound and uses thereof
PT3908582T (pt) Formas sólidas compreendendo (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-4-il)oxi)metil) benzil)piperazin-1-il)-3-fluorobenzonitrilo e seus sais, e composições compreendendo e métodos de utilização dos mesmos
MX2019015177A (es) Formulaciones farmaceuticas de n-(2-(2-(dimetilamino)etoxi)-4-meto xi-5((4-(1-metil-1h-indol-3-il)pirimidin-2-il)amino)fenil)acrilam ida y las sales de ellas.
MY146403A (en) F, g, h, i and k crystal forms of imatinib mesylate
MX2019004375A (es) Inhibidores de bromodominios.
EA201990940A1 (ru) ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
RU2007144522A (ru) Производные пиримидиламинобензамида для лечения синдрома гиперэозинофилии
SI3124025T1 (en) Combination of 3 - ((3 - ((4- (4-morpholinylmethyl) -1H-pyrrol-2-yl) methylene) -2-oxo-2,3-dihydro-1H-indol-5-yl) 1,3-TIAZOLIDINE-2,4-DION AND INHIBITOR OF TIROZINE KINAZE EGFR